Effect of promoter strength on protein expression and immunogenicity of an HSV-1 amplicon vector encoding HIV-1 Gag

Vaccine

Volumn 25, Issue 9, 2007, Pages 1634-1646

  Santos, Kathlyn ^a   Duke, Cindy M P ^a   Rodriguez Colon, Sol M ^a   Dakwar, Anthony ^a,b   Fan, Shongshan ^a   Keefer, Michael C ^a   Federoff, Howard J ^a   Frelinger, John G ^a   Bowers, William J ^a   Dewhurst, Stephen ^a  

^a UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

^b UNIVERSITY AT BUFFALO   (United States)

Author keywords

Dendritic cells (DC); Gag; HIV vaccines; HSV 1 amplicon vectors; Transcriptional control elements

Indexed keywords

GAG PROTEIN; HERPESVIRUS VECTOR; HUMAN IMMUNODEFICIENCY VIRUS ANTIGEN;

AMPLICON; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIGEN EXPRESSION; ARTICLE; BAGG ALBINO MOUSE; BIOPSY; CELL CULTURE; CONTROLLED STUDY; CORRELATION ANALYSIS; DENDRITIC CELL; DRUG DELIVERY SYSTEM; EXPRESSION VECTOR; FEMALE; GENE TRANSFER; HERPES SIMPLEX VIRUS 1; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNE RESPONSE; IMMUNOGENICITY; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; T LYMPHOCYTE;

3T3 CELLS; AIDS VACCINES; ANIMALS; CELL LINE; CELLS, CULTURED; DENDRITIC CELLS; FEMALE; GENE EXPRESSION REGULATION, VIRAL; GENE PRODUCTS, GAG; GENES, GAG; GENETIC VECTORS; HERPESVIRUS 1, HUMAN; HIV-1; HUMANS; MICE; MICE, INBRED BALB C; PROMOTER REGIONS (GENETICS); T-LYMPHOCYTES; TRANSCRIPTION, GENETIC;

EID: 33846210582     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2006.11.004     Document Type: Article

References (48)

1. Spaete R.R., and Frenkel N. The herpes simplex virus amplicon: a new eucaryotic defective-virus cloning-amplifying vector. Cell 30 1 (1982) 295-304
2. Geller A.I., and Breakefield X.O. A defective HSV-1 vector expresses Escherichia coli beta-galactosidase in cultured peripheral neurons. Science 241 4873 (1988) 1667-1669
3. Willis R.A., Bowers W.J., Turner M.J., Fisher T.L., Abdul-Alim C.S., Howard D.F., et al. Dendritic cells transduced with HSV-1 amplicons expressing prostate-specific antigen generate antitumor immunity in mice. Hum Gene Ther 12 15 (2001) 1867-1879
4. Hocknell P.K., Wiley R.D., Wang X., Evans T.G., Bowers W.J., Hanke T., et al. Expression of human immunodeficiency virus type 1 gp120 from herpes simplex virus type 1-derived amplicons results in potent, specific, and durable cellular and humoral immune responses. J Virol 76 11 (2002) 5565-5580
5. Wang X., Wiley R.D., Evans T.G., Bowers W.J., Federoff H.J., and Dewhurst S. Cellular immune responses to helper-free HSV-1 amplicon particles encoding HIV-1 gp120 are enhanced by DNA priming. Vaccine 21 19-20 (2003) 2288-2297
6. Bowers W.J., Mastrangelo M.A., Stanley H.A., Casey A.E., Milo Jr. L.J., and Federoff H.J. HSV amplicon-mediated Abeta vaccination in Tg2576 mice: differential antigen-specific immune responses. Neurobiol Aging 26 4 (2005) 393-407
7. Gorantla S., Santos K., Meyer V., Dewhurst S., Bowers W.J., Federoff H.J., et al. Human dendritic cells transduced with herpes simplex virus amplicons encoding human immunodeficiency virus type 1 (HIV-1) gp120 elicit adaptive immune responses from human cells engrafted into NOD/SCID mice and confer partial protection against HIV-1 challenge. J Virol 79 4 (2005) 2124-2132
8. Zibert A., Thomassen A., Muller L., Nguyen L., Glouchkova L., Fraefel C., et al. Herpes simplex virus type-1 amplicon vectors for vaccine generation in acute lymphoblastic leukemia. Gene Ther 12 23 (2005) 1707-1717
9. Herrlinger U., Jacobs A., Quinones A., Woiciechowsky C., Sena-Esteves M., Rainov N.G., et al. Helper virus-free herpes simplex virus type 1 amplicon vectors for granulocyte-macrophage colony-stimulating factor-enhanced vaccination therapy for experimental glioma. Hum Gene Ther 11 10 (2000) 1429-1438
10. Tolba K.A., Bowers W.J., Hilchey S.P., Halterman M.W., Howard D.F., Giuliano R.E., et al. Development of herpes simplex virus-1 amplicon-based immunotherapy for chronic lymphocytic leukemia. Blood 98 2 (2001) 287-295
11. Olschowka J.A., Bowers W.J., Hurley S.D., Mastrangelo M.A., and Federoff H.J. Helper-free HSV-1 amplicons elicit a markedly less robust innate immune response in the CNS. Mol Ther 7 2 (2003) 218-227
12. Tyler C.M., Wuertzer C.A., Bowers W.J., and Federoff H.J. HSV amplicons: neuro applications. Curr Gene Ther 6 3 (2006) 337-350
13. Epstein A.L. HSV-1-based amplicon vectors: design and applications. Gene Ther 12 Suppl. 1 (2005) S154-S158
14. Liu M., Tang J., Wang X., Yang T., and Geller A.I. Enhanced long-term expression from helper virus-free HSV-1 vectors packaged in the presence of deletions in genes that modulate the function of VP16, U L 46 and U L 47. J Neurosci Methods 145 1-2 (2005) 1-9
15. Breakefield X.O., and Geller A.I. Gene transfer into the nervous system. Mol Neurobiol 1 4 (1987) 339-371
16. Hagmann M., Georgiev O., and Schaffner W. The VP16 paradox: herpes simplex virus VP16 contains a long-range activation domain but within the natural multiprotein complex activates only from promoter-proximal positions. J Virol 71 8 (1997) 5952-5962
17. Herrera F.J., and Triezenberg S.J. VP16-dependent association of chromatin-modifying coactivators and underrepresentation of histones at immediate-early gene promoters during herpes simplex virus infection. J Virol 78 18 (2004) 9689-9696
18. Arnosti D.N., Preston C.M., Hagmann M., Schaffner W., Hope R.G., Laughlan G., et al. Specific transcriptional activation in vitro by the herpes simplex virus protein VP16. Nucleic Acids Res 21 24 (1993) 5570-5576
19. Garg S., Oran A.E., Hon H., and Jacob J. The hybrid cytomegalovirus enhancer/chicken beta-actin promoter along with woodchuck hepatitis virus posttranscriptional regulatory element enhances the protective efficacy of DNA vaccines. J Immunol 173 1 (2004) 550-558
20. Barouch D.H., Yang Z.Y., Kong W.P., Korioth-Schmitz B., Sumida S.M., Truitt D.M., et al. A human T-cell leukemia virus type 1 regulatory element enhances the immunogenicity of human immunodeficiency virus type 1 DNA vaccines in mice and nonhuman primates. J Virol 79 14 (2005) 8828-8834
21. Chapman B.S., Thayer R.M., Vincent K.A., and Haigwood N.L. Effect of intron A from human cytomegalovirus (Towne) immediate-early gene on heterologous expression in mammalian cells. Nucleic Acids Res 19 14 (1991) 3979-3986
22. Norman J.A., Hobart P., Manthorpe M., Felgner P., and Wheeler C. Development of improved vectors for DNA-based immunization and other gene therapy applications. Vaccine 15 8 (1997) 801-803
23. Chakrabarti B.K., Ling X., Yang Z.Y., Montefiori D.C., Panet A., Kong W.P., et al. Expanded breadth of virus neutralization after immunization with a multiclade envelope HIV vaccine candidate. Vaccine 23 26 (2005) 3434-3445
24. Huang Y., Kong W.P., and Nabel G.J. Human immunodeficiency virus type 1-specific immunity after genetic immunization is enhanced by modification of Gag and Pol expression. J Virol 75 10 (2001) 4947-4951
25. Chinnasamy D., Chinnasamy N., Enriquez M.J., Otsu M., Morgan R.A., and Candotti F. Lentiviral-mediated gene transfer into human lymphocytes: role of HIV-1 accessory proteins. Blood 96 4 (2000) 1309-1316
26. Halene S., Wang L., Cooper R.M., Bockstoce D.C., Robbins P.B., and Kohn D.B. Improved expression in hematopoietic and lymphoid cells in mice after transplantation of bone marrow transduced with a modified retroviral vector. Blood 94 10 (1999) 3349-3357
27. Bowers W.J., Howard D.F., Brooks A.I., Halterman M.W., and Federoff H.J. Expression of vhs and VP16 during HSV-1 helper virus-free amplicon packaging enhances titers. Gene Ther 8 2 (2001) 111-120
28. Stavropoulos T.A., and Strathdee C.A. An enhanced packaging system for helper-dependent herpes simplex virus vectors. J Virol 72 9 (1998) 7137-7143
29. Bowers W.J., Howard D.F., and Federoff H.J. Discordance between expression and genome transfer titering of HSV amplicon vectors: recommendation for standardized enumeration. Mol Ther 1 3 (2000) 294-299
30. Lutz M.B., Kukutsch N., Ogilvie A.L., Rossner S., Koch F., Romani N., et al. An advanced culture method for generating large quantities of highly pure dendritic cells from mouse bone marrow. J Immunol Methods 223 1 (1999) 77-92
31. Simm M., Shahabuddin M., Chao W., Allan J.S., and Volsky D.J. Aberrant Gag protein composition of a human immunodeficiency virus type 1 vif mutant produced in primary lymphocytes. J Virol 69 7 (1995) 4582-4586
32. Xia W., Bringmann P., McClary J., Jones P.P., Manzana W., Zhu Y., et al. High levels of protein expression using different mammalian CMV promoters in several cell lines. Protein Expr Purif 45 1 (2006) 115-124
33. Xu Z.L., Mizuguchi H., Ishii-Watabe A., Uchida E., Mayumi T., and Hayakawa T. Optimization of transcriptional regulatory elements for constructing plasmid vectors. Gene 272 1-2 (2001) 149-156
34. Xu Z.L., Mizuguchi H., Ishii-Watabe A., Uchida E., Mayumi T., and Hayakawa T. Strength evaluation of transcriptional regulatory elements for transgene expression by adenovirus vector. J Control Release 81 1-2 (2002) 155-163
35. Wang S., Farfan-Arribas D.J., Shen S., Chou T.H., Hirsch A., He F., et al. Relative contributions of codon usage, promoter efficiency and leader sequence to the antigen expression and immunogenicity of HIV-1 Env DNA vaccine. Vaccine 24 21 (2006) 4531-4540
36. Egan M.A., Megati S., Roopchand V., Garcia-Hand D., Luckay A., Chong S.Y., et al. Rational design of a plasmid DNA vaccine capable of eliciting cell-mediated immune responses to multiple HIV antigens in mice. Vaccine 24 21 (2006) 4510-4523
37. Deml L., Speth C., Dierich M.P., Wolf H., and Wagner R. Recombinant HIV-1 Pr55gag virus-like particles: potent stimulators of innate and acquired immune responses. Mol Immunol 42 2 (2005) 259-277
38. Mata M., Travers P.J., Liu Q., Frankel F.R., and Paterson Y. The MHC class I-restricted immune response to HIV-gag in BALB/c mice selects a single epitope that does not have a predictable MHC-binding motif and binds to Kd through interactions between a glutamine at P3 and pocket D. J Immunol 161 6 (1998) 2985-2993
39. Mariani R., Rutter G., Harris M.E., Hope T.J., Krausslich H.G., and Landau N.R. A block to human immunodeficiency virus type 1 assembly in murine cells. J Virol 74 8 (2000) 3859-3870
40. Wong S.B., and Siliciano R.F. Contribution of virus-like particles to the immunogenicity of human immunodeficiency virus type 1 Gag-derived vaccines in mice. J Virol 79 3 (2005) 1701-1712
41. Akahata W., Yang Z.Y., and Nabel G.J. Comparative immunogenicity of human immunodeficiency virus particles and corresponding polypeptides in a DNA vaccine. J Virol 79 1 (2005) 626-631
42. Chakrabarti B.K., Kong W.P., Wu B.Y., Yang Z.Y., Friborg J., Ling X., et al. Modifications of the human immunodeficiency virus envelope glycoprotein enhance immunogenicity for genetic immunization. J Virol 76 11 (2002) 5357-5368
43. Mascola J.R., Sambor A., Beaudry K., Santra S., Welcher B., Louder M.K., et al. Neutralizing antibodies elicited by immunization of monkeys with DNA plasmids and recombinant adenoviral vectors expressing human immunodeficiency virus type 1 proteins. J Virol 79 2 (2005) 771-779
44. Smith R.L., Traul D.L., Schaack J., Clayton G.H., Staley K.J., and Wilcox C.L. Characterization of promoter function and cell-type-specific expression from viral vectors in the nervous system. J Virol 74 23 (2000) 11254-11261
45. Wright A., Semyonov A., Dawes G., Crameri A., Lyons R., Stemmer W.P., et al. Diverse plasmid DNA vectors by directed molecular evolution of cytomegalovirus promoters. Hum Gene Ther 16 7 (2005) 881-892
46. Itano A.A., and Jenkins M.K. Antigen presentation to naive CD4 T cells in the lymph node. Nat Immunol 4 8 (2003) 733-739
47. Jenkins M.K., Khoruts A., Ingulli E., Mueller D.L., McSorley S.J., Reinhardt R.L., et al. In vivo activation of antigen-specific CD4 T cells. Annu Rev Immunol 19 (2001) 23-45
48. Reinhardt R.L., Khoruts A., Merica R., Zell T., and Jenkins M.K. Visualizing the generation of memory CD4 T cells in the whole body. Nature 410 6824 (2001) 101-105